US-based XOMA Corporation (XOMA) has received Orphan Drug Designation from the US Food and Drug Administration (FDA) for its IL-1 beta modulating antibody 'gevokizumab' for the treatment of pyoderma gangrenosum (PG). Gevokizumab is a ...
Tags: Orphan Drug, Medicine
DTect-All(TM) platform will be used to screen for GPCR-directed allosteric modulator antibodies Domain Therapeutics, a biopharmaceutical company specializing in the research and development of new drug candidates targeting G ...
Tags: DTect-All(TM)
American biotechnology firm XOMA has obtained orphan drug designation by the US Food & Drug Administration (FDA) for its IL-1 beta modulating antibody 'Gevokizumab', which treats non-infectious intermediate, posterior, pan-uveitis, or ...
Tags: American biotechnology, XOMA, orphan drug, FDA